7th partner for AI treatment discovery startup

Israel’s CytoReason (see here previously) has added SPI (part of Japanese giant Sumitomo) to its growing list of partners.  SPI will use CytoReason’s unique immune focused machine learning platform and represent CytoReason in the Japanese market – the third largest globally.

https://www.timesofisrael.com/japanese-pharmaceutical-firm-taps-israels-cytoreason-for-ai-drug-development/

https://www.calcalistech.com/ctech/articles/0,7340,L-3918547,00.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.